Najat Khan leaving J&J for Recursion
Plus: Innovent hires Nageatte Ibrahim as oncology CMO, and updates from Endeavor and Vittoria
Najat Khan will depart as chief data science officer and global head of strategy, portfolio and operations for R&D at the Johnson & Johnson Innovative Medicine unit of Johnson & Johnson (NYSE:JNJ) to become chief R&D officer, chief commercial officer and a board member at Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). Recursion is a techbio drug discovery company that uses its phenotypic screening platform to predict targets. Khan was a guest on The BioCentury Show last year.
Innovent Biologics Inc. (HKEX:1801) hired Nageatte Ibrahim as oncology CMO. Ibrahim was VP, global clinical development, oncology at Merck & Co. Inc. (NYSE:MRK), where she held roles for nearly a decade...